It is a "Big" deal is Vyvanse growth is flat. Shire reports and responds to shareholders. They can't just keep raising the price of Vyvanse due to managed care. They have to show consistant growth to keep shareholders happy. When they fail to do this, cuts need to be made (HELLO! This restructuring MESS!) Why is ADHD going through a re-structure? Because the med is not growing and they need to cut liabilities! It's not hard. It will happen again too if the med continues to stay flat.
The next shoe to drop will be our goals. They WILL become more aggressive to offset the lack of growth. Just wait, and when reps begin to make 2-4k a Q, then you will see.
